Research progress of miR-423-5p, TFFs and NAG-1 in anti NASIDs induced gastric mucosal injury

doi:10.12092/j.issn.1009-2501.2018.09.017

Abstract

Abstract:

Nonsteroidal anti-inflammatory drugs (NSAIDs) are a class of antipyretic and analgesic drugs widely used in clinic. However, gastric mucosal injury caused by NSAIDs is also common. To clarify the pathogenesis of gastrointestinal mucosal injury induced by NSAIDs, and to find new anti-inflammatory drugs with good anti-inflammatory effect and few side effects of gastric mucosal injury are the research hotspots of many medical workers. In recent years, researches at home and abroad have shown that microRNA423-5p, TFFs and NAG-1 are involved in the process of gastric mucosal injury, but the relationship among the aforementioned three is still unclear. This article reviews the mechanism of gastric mucosal injury induced by NASIDs, their properties and their interaction in gastric mucosal injury.

Key words: mechanism of gastric mucosal injury induced by NSAIDs, miR-423-5p, TFFs, NAG-1

CLC Number:

R573

LI Xiaomei, LI Xiaoqin, HE Haibo, ZHANG Yongfeng, XU Haiyan, QIN Huilin, ZHANG Jihong, WANG Junzhi, LUO Tao. Research progress of miR-423-5p, TFFs and NAG-1 in anti NASIDs induced gastric mucosal injury[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(9): 1068-1074.

References

［1］Yuan JQ, Tsoi KK, Yang M, et al. Systematic review with network meta-analysis: comparative effectiveness and safety of strategies for preventing NSAID-associated gastrointestinal toxicity［J］. Aliment Pharmacol Ther, 2016, 43 (12):1262-1275.
［2］Yang M, He M, Zhao M, et al. Proton pump inhibitors for preventing non-steroidal anti-inflammatory drug induced gastrointestinal toxicity: a systematic review［J］. Curr Med Res Opin,2017, 33 (6): 973-980.
［3］Sostres C,Gargallo CJ, Lanas A.Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage ［J］. Arthritis Res Ther, 2013, 15 (S3): S3.
［4］Yandrapu H, Sarosiek J. Protective factors of the gastric and duodenal mucosa: an overview ［J］. Curr Gastroenterol Rep, 2015, 17 (6): 24.
［5］陈光治, 张志芳. 胃大部分切除术与单纯修补术治疗胃溃疡穿孔疗效比较［J］. 现代仪器与医疗, 2016, 22 (2): 96-97.
［6］Kangwan N, Park JM, Hahm KB.Development of GI-safe NSAID; progression from the bark of willow tree to modern pharmacology［J］. Curr Opin Pharmacol, 2014, 19: 17-23.
［7］Liu R, Zhang CN, Hu ZB, et al.A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis ［J］. Eur J Cancer, 2011, 47 (5): 784-791.
［8］Liu JJ, Wang X, Yang XN, et al. miRNA423-5p regulates cell proliferation and invasion by targeting trefoil factor 1 in gastric cancer cells ［J］. Cancer Lett, 2014, 347 (1): 98-104.
［9］覃慧林, 张永峰, 王心怡, 等. 木瓜乙酸乙酯萃取部位对急性胃溃疡小鼠胃黏膜中miR-423-5p、TFF1和p53表达的影响［J］. 中药药理与临床, 2016, 32 (3): 80-82.
［10］Liggett JL, Zhang X, Eling TE, et al. Anti-tumor activity of non-steroidal anti-inflammatory drugs: cyclooxygenase-independent targets ［J］. Cancer Lett, 2014, 346 (2): 217-224.
［11］Zhao Y, Huang J, Zhang L, et al.MiR-133b is frequently decreased in gastric cancer and its overexpression reduces the metastatic potential of gastric cancer cells［J］. BMC Cancer, 2014, 14: 34.
［12］Nadeem A, Ashraf MR, Javed M, et al. Review-MicroRNAs: A new paradigm towards mechanistic insight of diseases ［J］. Pak J Pharm Sci, 2018, 31 (5): 2017-2026.
［13］Hata A,Kashima R.Dysregulation of microRNA biogenesis machinery in cancer ［J］. Crit Rev Biochem Mol Biol, 2016, 51 (3):121-134.
［14］Cha WZ, Fan RG, Miao YF, et al. MicroRNAs as novel endogenous targets for regulation and therapeutic treatments［J］. Medchemcomm, 2017, 9 (3):396-408.
［15］Tong F, Cao P, Yin Y, et al. MicroRNAs in gastric cancer: from benchtop to bedside ［J］. Dig Dis Sci, 2014, 59 (1): 24-30.
［16］Aihara E, Engevik KA, Montrose MH.Trefoil Factor Peptides and Gastrointestinal Function［J］. Annu Rev Physiol, 2017, 79: 357-380.
［17］Busch M, Dünker N. Trefoil factor family peptides-friends or foes?［J］Biomol Concepts, 2015, 6 (5/6):343-359.
［18］Donley C, McClelland K, McKeen HD, et al. Identification of RBCK1 as a novel regulator of FKBPL: implications for tumor growth and response to tamoxifen［J］. Oncogene, 2014, 33 (26): 3441-3450.
［19］Judd LM, Chalinor HV, Walduck A, et al. TFF2 deficiency exacerbates weight loss and alters immune cell and cytokine profiles in DSS colitis, and this cannot be rescued by wild-type bone marrow［J］. Am J Physiol Gastrointest Liver Physiol, 2015, 308 (1): G12-G24.
［20］Liu JJ, Wang X, Yang XN, et al. miRNA423-5p regulates cell proliferation and invasion by targeting trefoil factor 1 in gastric cancer cells ［J］. Cancer Lett, 2014, 347 (1): 98-104.
［21］Hoffmann W. TFF2, a MUC6-binding lectin stabilizing the gastric mucus barrier and more (Review) ［J］. Int J Oncol, 2015, 47(3): 806-816.
［22］Kuzminov FI, Gorbunov MY. Energy dissipation pathways in photosystem 2 of the diatom, Phaeodactylum tricornutum, under high-light conditions ［J］. Photosynth Res, 2016, 127 (2): 219-235.
［23］Goldenring JR. Pyloric metaplasia, pseudopyloric metaplasia, ulcer-associated cell lineage and spasmolytic polypeptide-expressing metaplasia: reparative lineages in the gastrointestinal mucosa［J］. J Pathol, 2018, 245 (2):132-137.
［24］Park DJ, Kim SE.The role of IL-10 in gastric spasmolytic polypeptide-expressing metaplasia-related carcinogenesis［J］. Gut Liver, 2017, 11 (6): 741-742.
［25］Hu JH, Shi Y, Wang C, et al.Role of intestinal trefoil factor in protecting intestinal epithelial cells from burn-induced injury［J］. Sci Rep, 2018, 8(1): 3201. doi: 10.1038/s41598-018-21282-4.
［26］Bijeliｃ N, Belovari T, Tolui Levak M, et al. Localization of trefoil factor family peptide 3 (TFF3) in epithelial tissues originating from the three germ layers of developing mouse embryo［J］. Bosn J Basic Med Sci, 2017, 17 (3):241-247.
［27］Colucci R, Antonioli L, Bernardini N, et al. Nonsteroidal anti-inflammatory drug-activated gene-1 plays a role in the impairing effects of cyclooxygenase inhibitors on gastric ulcer healing［J］.J Pharmacol Exp Ther, 2012, 342 (1):140-149.
［28］Yang MH, Kim J, Khan IA, et al. Nonsteroidal anti-inflammatory drug activated gene-1 (NAG-1) modulators from natural products as anti-cancer agents［J］. Life Sci, 2014, 100 (2):75-84.
［29］Woo SM, Min KJ, Kim S, et al.Silibinin induces apoptosis of HT29 colon carcinoma cells through early growth response-1 (EGR-1)-mediated non-steroidal anti-inflammatory drug-activated gene-1 (NAG-1) up-regulation［J］. Chem Biol Interact, 2014, 211: 36-43.
［30］Lim JH, Park JW, Min DS, et al. NAG-1 up-regulation mediated by EGR-1 and p53 is critical for quercetin-induced apoptosis in HCT116 colon carcinoma cells ［J］. Apoptosis, 2007, 12: 411-421.
［31］Nakao H, Seko A, Ito Y, et al. PDI family protein ERp29 recognizes P-domain of molecular chaperone calnexin［J］. Biochem Biophys Res Commun, 2017, 487 (3):763-767.
［32］Shah AA, Leidinger P, Keller A, et al. The intestinal factor TFF3 and a miRNA network regulate murine caloric metabolism ［J］. RNA Biology, 2011, 8 (1): 77-81.
［33］Miura S, Nozawa M, Nei M. Evolutionary changes of the target sites of two microRNAs encoded in the Hox gene cluster of Drosophila and other insect species ［J］. Genome Biol Evol, 2011, 3 (1): 29-39.
［34］陈国彬，任建林.微小RNA423-5p调控三叶因子1基因表达及对胃黏膜上皮细胞生物学行为影响［D］. 福建：福建医科大学, 2015, 6-8.
［35］Khoder G, Al-Menhali AA, Al-Yassir F, et al.Potential role of probiotics in the management of gastric ulcer［J］. Exp Ther Med, 2016, 12 (1): 3-17.
［36］Ock CY, Park JM, Han YM, et al.Genetic ablation or pharmacologic inhibition of autophagy mitigated NSAID-associated gastric damages［J］. J Mol Med (Berl), 2017, 95 (4): 405-416.
［37］Kandasamy J, Huda S, Ambalavanan N, et al. Inflammatory signals that regulate intestinal epithelial renewal, differentiation, migration and cell death: Implications for necrotizing enterocolitis［J］. Pathophysiology, 2014, 21(1): 67-80.
［38］Goldenring JR. Pyloric metaplasia, pseudopyloric metaplasia, ulcer-associated cell lineage and spasmolytic polypeptide-expressing metaplasia: reparative lineages in the gastrointestinal mucosa［J］. J Pathol, 2018, 245 (2):132-137.
［39］Wang WZ, Li Z, Wang JW, et al. A functional polymorphism in TFF1 promoter is associated with the risk and prognosis of gastric cancer［J］. Int J Cancer, 2018, 142(9):1805-1816.
［40］Soutto M, Ahmed M, Katsha, et al. TFF1 Acquires its tumor suppressor functions through regulation of p53 ［J］. Gastroenterology, 2014, 146 (5): S627-S627.
［41］Soutto M, Chen Z, Saleh MA, et al.TFF1 activates p53 through down-regulation of miR-504 in gastric cancer［J］. Oncotarget, 2014, 5 (14): 5663-5673.
［42］Busch M, Grobe-Kreul J, Wirtz JJ, et al. Reduction of the tumorigenic potential of human retinoblastoma cell lines by TFF1 overexpression involves p53/caspase signaling and miR-18a regulation［J］. Int J Cancer, 2017, 141 (3): 549-560.
［43］覃慧林, 张永峰, 贺海波, 等. 木瓜三萜抗吲哚美辛诱导RGM-1细胞凋亡的作用［J］. 中国临床药理学与治疗学, 2016, 21(12): 1347-1353.
［44］Yuseok Moon. NSAID-activated gene 1 and its implications for mucosal integrity and intervention beyond NSAIDs ［J］. Pharmacol Res, 2017, 121:122-128.